499 assets in Hepatocellular Carcinoma

Defactinib

Epalrestat

Eparlitozoviril

Fexagratinib

Geptanolimab

gpc3-car-t cells

Gsk-2636771

Hdac Inhibitor Cxd101

hlx43

hlx53

Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide

Indometacinum

Ino 9012

Ipatasertib

Irpagratinib

Kras Tcr-Transduced Pbl

Larotrectinib

Ligufalimab

Lparomlimab

NKT2152

Olanzapine

Pertuzumab

Pevonedistat

Pimurutamab

rbs2418

Shr-1826

SIN-1A

Taurursodiol

Tocilizumab

Trastuzumab Emtansine

Tuvonralimab

Vancomycin

Vismodegib

Visugromab

YH 001

zg005

ACETIC

Adavosertib

Allostim®

Aspirin

Avelumab

Bavituximab

Becavizumab

Fianlimab

Futibatinib

Granisetron

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

Liocyx-M

Neoantigen Dendritic Cell Vaccine

Nivestim